



Pergamon

Tetrahedron Letters 41 (2000) 7207–7209

TETRAHEDRON
LETTERS

Synthesis of a novel bifunctional chelating agent for actinium complexation

Ali Ouadi,^{a,b,c,*} Anthony Loussouarn,^c Patricia Remaud,^c Laurence Morandeau,^c
Christos Apostolidis,^b Claude Musikas,^a Alain Faivre-Chauvet^c
and Jean-François Gestin^c

^aUnité Mixte de Recherche 6457, Laboratoire Subatech-Ecole des Mines de Nantes, 4 rue Alfred Kastler, BP 20722, 44307 Nantes cedex 3, France

^bEuropean Institute for Transuranium Elements, Postfach 2340, D-76125 Karlsruhe, Germany

^cChimie des Bioconjugués, U. 463 INSERM, 9 Quai Moncoussu, 44093 Nantes Cedex, France

Received 18 May 2000; accepted 13 July 2000

Abstract

A novel bifunctional chelating agent for actinium was synthesized in eight steps. Bimolecular cyclization between an iminodiester and a polyamine was achieved through the action of a molar equivalent of sodium methoxide. © 2000 Elsevier Science Ltd. All rights reserved.


Immunotherapy with radiolabeled antibodies should allow fairly specific targeting of some cancers.^{1,2} One promising candidate for such applications³ is ²²⁵Ac, an α -emitter. The very short range (< 100 μ m) of α particles and their high energy transfer should be conducive to efficient destruction of tumor cells, whereas normal cells should be relatively spared. The development of new bifunctional chelating agents (BCAs) is essential for this purpose, but no suitable BCA has been reported for ²²⁵Ac.^{4–6}

Our investigations, in agreement with other studies,⁵ indicated that HEHA (1,4,7,10,13,16-hexaazacarboxylmethyl-1,4,7,10,13,16-hexaazacyclooctadecane) was the best candidate for ²²⁵Ac complexation (Scheme 1), which led us to synthesize the C-functionalized analogue.


We prepared 2-(4-isothiocyanatobenzyl)-1,4,7,10,13,16-hexakis (2-carboxymethyl)hexaazacyclooctadecane, which is functionalized at C-2 on the ring by an isothiocyanate termination for covalent attachment to biomolecules (Scheme 2).

A commercial product, 4-nitrophenylalanine **1**, was used as starting material. Treatment of **1** with HCl gas in methanol yielded 4-nitrophenylalanine methyl ester hydrochloride. *N*-((methoxycarbonyl)methyl)-4-nitrophenylalanine methyl ester was prepared by reacting 3 equivalents of

* Corresponding author. Fax: 49 7247 951 593; e-mail: ouadi@itu.fzk.de



Scheme 1. HEHA



Scheme 2. Reagents: (i) MeOH/HClg; (ii) NEt₃/BrCH₂CO₂Me/THF; (iii) NaOMe/tetraethylenepentamine/MeOH/reflux; (iv) BH₃/THF; (v) Na₂CO₃/BrCH₂CO₂tBu/DMF; (vi) SnCl₂/MeOH; (vii) TFA; (viii) CSCl₂

methylbromoacetate and triethylamine with 1 equivalent of 4-nitrophenylalanine methyl ester. Treatment with tetraethylenepentamine in the presence of sodium oxide in refluxing methanol induced macrocyclization, producing the cyclic diamide **2** in a 50% yield.⁷ Reduction with BH₃ afforded after treatment with HCl gas and purification by anion-exchange chromatography 2-(4-nitrobenzyl)-1,4,7,10,13,16-hexaazacyclooctadecane **3** in a 55% yield. The hexa-*t*-butyl ester **4** was prepared by reacting 6 equivalents of *tert*-butyl bromoacetate and 11 equivalents of sodium carbonate with 1 equivalent of hexaazacyclooctadecane. The nitrobenzyl function was selectively reduced by using tin chloride in ethanol to obtain the aminobenzyl compound. Cleavage of the ester groups with trifluoroacetic acid, followed by purification on an ion-exchange chromatography column, gave *p*-aminobenzyl-HEHA **5**,⁸ and treatment with thiophosgene yielded the final compound, *p*-isothiocyanatobenzyl-HEHA **6**.

Construction of the polyazamacrocycle ring is crucial for the successful synthesis of a macrocycle BCA. However, previously reported cyclization methodologies^{9–14} proved unsatisfactory in our

hands. The reaction between *N*-methoxycarbonylmethyl-*p*-nitrophenylalanine methyl ester and tetraethylenepentamine, upon refluxing in methanol for several days in the absence of sodium methoxide, failed to yield the desired product. Therefore, an improved procedure was developed for the bimolecular cyclization between an iminodiester and a polyamine through the action of a molar equivalent of sodium methoxide. A 50% yield was obtained, which enabled us to prepare the bifunctional dioxoaza macrocycle without any need for high dilution. This method is simple and easy to perform, allowing the preparation of functionalized macrocyclic polyamines of varying ring sizes.

References

1. Couturier, O.; Faivre-Chauvet, A.; Filippovich, I. V.; Thedrez, P.; Saï-Maurel, C.; Bardiès, M.; Mishra, A. K.; Gauvrit, M.; Blain, G.; Apostolidis, C.; Molinet, R.; Abbé, J. C.; Bataille, R.; Wijdenes, J.; Chatal, J. F.; Chérel, M. *Clin. Cancer. Res.* **1999**, *5*, 3165–3170.
2. Macklis, R. M.; Kinsey, B. M.; Kassis, A. I.; Ferrara, J. L.; Atcher, R. W.; Hines, J. J.; Coleman, C. N.; Adelstein, S. J.; Burakoff, S. J. *Science* **1988**, *240*, 1024–1026.
3. Kaspersen, F. M.; Bos, E.; Doornmalen, A. V.; Geerlings, M. W.; Apostolidis, C.; Molinet, R. *Nucl. Med. Commun.* **1995**, *16*, 468–476.
4. Davis, I. A.; Glowienka, K. A.; Boll, R. A.; Deal, K. A.; Brechbiel, M. W.; Stabin, M.; Bochsler, P. N.; Mirzadeh, S.; Kennel, J. S. *Nucl. Med. Biol.* **1999**, *26*, 581–589.
5. Deal, K. A.; Davis, I. A.; Mirzadeh, S.; Kennel, J. S.; Brechbiel, M. W. *J. Med. Chem.* **1999**, *42*, 2988–2992.
6. Grote Gansey, M. H. B.; de Haan, A. S.; Bos, E. S.; Verboom, W.; Reinhoudt, D. N. *Bioconj. Chem.* **1999**, *10*, 610–623.
7. Preparation of **2**: Sodium (20 mmol) was dissolved in dry methanol (100 ml) at room temperature under a nitrogen atmosphere, and tetraethylenepentamine (18 mmol) and *N*-((methoxycarbonyl)methyl)-4-nitrophenylalanine methyl ester (18 mmol) were then added to this solution. After the solution was refluxed for 72 h, the solvent was removed and the residue was purified on silica gel chromatography with chloroform:methanol:NH₃ (aq) (75:20:5), affording a brown powder with a yield of 50%.
8. All compounds gave satisfactory spectroscopic and analytical data. Representative data for selected compounds are: compound **2**: MS (M+1): 422, IR (K_r, cm⁻¹): 3287 (NH), 3287–2842 (Ar–C–H), 1656 (C=O), 1517 and 1345 (NO₂), ¹H NMR (250 MHz, CDCl₃): δ 8.17 (d, 2H), 7.57 (s, NH amide), 7.40 (d, 2H), 7.27 (s, NH amide), 3.14–3.48 (m, 9H), 2.6–2.9 (m, 11H), ¹³C NMR (CDCl₃): CO: 175, 145, 130, 123, 55, 52, 40; compound **3**: MS (M+1): 394, IR (K_r, cm⁻¹): 3428 (NH), 2961–2759 (Ar–C–H), 1518 and 1349 (NO₂), ¹H NMR (250 MHz, CDCl₃): δ 8.06 (d, 2H), 7.27 (d, 2H), 2.3–2.9 (m, 25H); compound **5**: MS (M+1): 712, ¹H NMR (250 MHz, D₂O): δ 7.08 (d, 2H), 6.80 (d, 2H), 2.5–4.0 (m, 37H).
9. Richman, J. E.; Atkins, T. J. *J. Am. Chem. Soc.* **1974**, *96*, 2268–2270.
10. Vellacio Jr., F.; Penzar, R. V.; Kemp, D. S. *Tetrahedron Lett.* **1977**, *6*, 547–550.
11. Tabushi, I. *Tetrahedron Lett.* **1977**, *12*, 1049–1052.
12. Moi, M. K.; Meares, C. F. *J. Am. Chem. Soc.* **1988**, *110*, 6266–6267.
13. Krakowiack, K. E.; Bradshaw, J. S.; Izatt, R. M. *J. Heterocycl. Chem.* **1990**, *27*, 1585–1589.
14. McMurry, T. J.; Brechbiel, M.; Kumar, K.; Gansow, O. A. *Bioconj. Chem.* **1992**, *3*, 108–117.